We measured early 2016/17 season influenza vaccine effectiveness (IVE) against influenza A(H3N2) in Europe using multicentre case control studies at primary care and hospital levels. IVE at primary care level was 44.1%, 46.9% and 23.4% among 0–14, 15–64 and ≥ 65 year-olds, and 25.7% in the influenza vaccination target group. At hospital level, IVE was 2.5%, 7.9% and 2.4% among ≥ 65, 65–79 and ≥ 80 year-olds. As in previous seasons, we observed suboptimal IVE against influenza A(H3N2)
Influenza A(H3N2), A(H1N1)pdm09 and B viruses co-circulated in Europe in 2014/15. We undertook a mul...
While influenza vaccines aim to decrease the incidence of severe influenza among high-risk groups, e...
International audienceWhile influenza vaccines aim to decrease the incidence of severe influenza amo...
International audienceWe measured early 2016/17 season influenza vaccine effectiveness (IVE) against...
We measured early 2016/17 season influenza vaccine effectiveness (IVE) against influenza A(H3N2) in ...
Background In 2021-2022, influenza A viruses dominated in Europe. The I-MOVE primary care network co...
International audienceIn a multicentre European hospital study we measured influenza vaccine effecti...
In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A...
BackgroundBetween October 2022 and January 2023, influenza A(H1N1)pdm09, A(H3N2) and B/Victoria viru...
Influenza vaccination strategies aim at protecting high-risk population from severe outcomes. Estima...
Background: Influenza A(H1N1)pdm09, A(H3N2) and B viruses were co-circulating in Europe between Se...
Influenza A(H3N2), A(H1N1)pdm09 and B viruses co-circulated in Europe in 2014/15. We undertook a mul...
While influenza vaccines aim to decrease the incidence of severe influenza among high-risk groups, e...
International audienceWhile influenza vaccines aim to decrease the incidence of severe influenza amo...
International audienceWe measured early 2016/17 season influenza vaccine effectiveness (IVE) against...
We measured early 2016/17 season influenza vaccine effectiveness (IVE) against influenza A(H3N2) in ...
Background In 2021-2022, influenza A viruses dominated in Europe. The I-MOVE primary care network co...
International audienceIn a multicentre European hospital study we measured influenza vaccine effecti...
In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A...
BackgroundBetween October 2022 and January 2023, influenza A(H1N1)pdm09, A(H3N2) and B/Victoria viru...
Influenza vaccination strategies aim at protecting high-risk population from severe outcomes. Estima...
Background: Influenza A(H1N1)pdm09, A(H3N2) and B viruses were co-circulating in Europe between Se...
Influenza A(H3N2), A(H1N1)pdm09 and B viruses co-circulated in Europe in 2014/15. We undertook a mul...
While influenza vaccines aim to decrease the incidence of severe influenza among high-risk groups, e...
International audienceWhile influenza vaccines aim to decrease the incidence of severe influenza amo...